Description
Docetaxel Brand names available in India?
Docetaxel is the generic name of the medication and is its international nonproprietary name. Docetaxel is marketed under the brand name Docetere among others.
Docetaxel is a chemotherapy medication that targets and destroys fast-dividing cells, like cancer cells. Docetaxel (DTX or DXL), is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. It may be used by itself or along with other chemotherapy medication.
Common side effects include hair loss, cytopenia (low blood cell counts), numbness, shortness of breath, nausea, vomiting, and muscle pains. Other severe side effects include allergic reactions and future cancers. Docetaxel induced pneumotoxicity is also a well recognized adverse effect which has to be identified timely and treated after withholding the drug. Side effects are more common in people with liver problems. Use during pregnancy may harm the baby. Docetaxel is in the taxane family of medications. It works by disrupting the normal function of microtubules and thereby stopping cell division.
Docetaxel was patented in 1986 and approved for medical use in 1995. It is on the World Health Organization’s List of Essential Medicines.Docetaxel is available as a generic medication.
Will this product be accessible across all regions of India?
The product – Docetere (Docetaxel) Injection will be available across India on request. Docetaxel is available in all the major cities in India – Delhi, Chandigarh, Jodhpur, Patna, Kolkata, Lucknow, Hyderabad, Chennai, Ahmedabad, Bangalore, and Pune. To get or place an order from Aark Pharmaceuticals, a pharma distributor in India, please call us at+91 9999156233, You can also make an inquiry by emailing us at sales@aarkpharma.co.in, sales@aarkpharma.com, WhatsApp: +91 9999156233.
NEWS / UPDATES
- Alembic Pharma Announces USFDA Approval For Docetaxel Injection.
- Zydus Lifesciences partners with Zhuhai Beihai Biotech for BEIZRAY commercialisation in the US.
- Zydus Lifesciences Licenses Cancer Drug in US.
- Sun Pharma announces USFDA approval for DOCEFREZTM (docetaxel) for Injection.
- Drugs@CDSCO.
- List of new drugs (r-DNA origin) approved for import and marketing in India during Jan, 2020 – Jun, 2024.
- Dr. Reddy’s announces the Launch of Docetaxel Injection USP.
Written By
Mr. Sandeep Tomar (D. Pharma)
Last updated
01 March 2025 | 07:25 AM (IST)